Floatz logo

Nivestim

Retinoblastoma

Xinhua Hospital, Shanghai Jiao Tong University School of Medicineprotein_peptidePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Retinoblastoma cohort.

Asset / SponsorPhaseRating
SUBA-ITRACONAZOLE COMPONENT ITRACONAZOLE
Samsung Medical Center
Phase 4BB
Thiotepa
Masonic Cancer Center, University of Minnesota
Phase 2BB
Cyclophosphamide
Seattle Children's Hospital
Phase 2BB
BUSULFANUM
Masonic Cancer Center, University of Minnesota
Phase 2BB
NOGITECAN
Emory University
Phase 2BB

View all 28 →

Same molecule, other indications

Nivestim is also rated in:

Burkitt lymphomaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
neutropeniaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →